Italian test maker DiaSorin puts down $1.8B for Luminex in diagnostics tie-up | Fierce Biotech
DIASORIN S.p.A. REPORT ON THE REMUNERATION POLICY AND FEES PAID 2020
Relazione_CG_Esercizio_31 12 2008_en
Results | DiaSorin
DiaSorin to Buy Covid-19 Test-Maker Luminex for $1.8 Billion - Bloomberg
/cloudfront-us-east-2.images.arcpublishing.com/reuters/34L6IFUZ2JLLDHCVNW34Y664HE.jpg "Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters")
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters
DiaSorin - The Diagnostic Specialist
Results | DiaSorin
Azioni Diasorin: Analisi Tecnica - Borsa Italiana
DiaSorin Inc. | LinkedIn
Diasorin Launches LIAISON IQ POC Reader with 10-Minute SARS-CoV-2 Antibody Test - COVID-19 - mobile.Labmedica.com
Homepage - DiaSorin Molecular
COVID-19 | Updates | DiaSorin
DiaSorin Italia S.p.A. | DiaSorin
Diasorin heads to the US with $1.8bn Luminex deal | Evaluate
Simplexa® SARS-CoV-2 Variants Direct (RUO) - DiaSorin Molecular
DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics
DiaSorin S.p.A. (DIA) Company Information - Simply Wall St
Annual Financial Report
DiaSorin, ricavi in calo nel primo semestre. +4% ex Covid
COVID-19 | Updates | DiaSorin
 "DiaSorin simplifies diagnostics by implementing a digital solution | Reply")
DiaSorin simplifies diagnostics by implementing a digital solution | Reply
DiaSorin | Saluggia
DiaSorin Said to Weigh Deal for Covid-Testing Rival Luminex - Bloomberg
Our history | DiaSorin
DiaSorin to Acquire Focus Diagnostics Unit for $300 Million | Clinical Lab Products
Annual Financial Report
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters
DiaSorin - The Diagnostic Specialist
DiaSorin warns of lower revenue as COVID-related demand fades, ET HealthWorld
Borsa: Milano frena ancora (-1,1%), pesano Diasorin e Stellantis - Notizie - Ansa.it
Milan: downside move for DiaSorin - Borsa Italiana
Meet our People | DiaSorin
Press Release
Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant
LIAISON® XL | DiaSorin
DiaSorin - The Diagnostic Specialist
proudtobeDiaSorin | DiaSorin
DiaSorin
DiaSorin buys out rival diagnostics firm Luminex for $1.8bn
Diasorin, il titolo vola in borsa dopo i conti del primo semestre: utili e ricavi in calo ma sopra le attese - MilanoFinanza News
DiaSorin : Taking on board the near-term difficulties -August 16, 2023 at 05:46 am| MarketScreener
Homepage - DiaSorin Molecular
DiaSorin | LinkedIn
DiaSorin - The Diagnostic Specialist
Milan: DiaSorin on the rise - Borsa Italiana
Annual Financial Report
DiaSorin | Saluggia
DiaSorin | Saluggia
DiaSorin concludes acquisition of Luminex for $1.8bn
Annual Financial Report
Untitled
